avizakimab (BOS161721) / Boston Pharma - LARVOL DELTA

Reversing Dysfunction of CCR9+ Regulatory T Cells by Targeting the IL-21/IL-17 Axis Improves Type 1 Diabetes. (PubMed, Diabetes Metab Syndr Obes) - "In the T1DM milieu, CCR9+ Tregs become dysfunctional and shift towards a pro-inflammatory phenotype, thereby exacerbating the autoimmune response. The anti-IL-21 monoclonal antibody Avizakimab can reverse the dysfunction of CCR9+ Tregs and ameliorate disease symptoms by inhibiting the IL-21/IL-17 axis, providing a novel potential strategy for the immunotherapy of T1DM and highlighting the translational potential of targeting this axis."

IO biomarker • Journal • Diabetes • Immunology • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • IL10 • IL17A • IL21

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care (clinicaltrials.gov) - P1b/2; N=143; Completed; Sponsor: Boston Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care (clinicaltrials.gov) - P1b/2; N=143; Active, not recruiting; Sponsor: Boston Pharmaceuticals; Trial primary completion date: Aug 2020 ➔ Nov 2020

Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus